These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

831 related articles for article (PubMed ID: 19177031)

  • 1. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference.
    Wallemacq P; Armstrong VW; Brunet M; Haufroid V; Holt DW; Johnston A; Kuypers D; Le Meur Y; Marquet P; Oellerich M; Thervet E; Toenshoff B; Undre N; Weber LT; Westley IS; Mourad M
    Ther Drug Monit; 2009 Apr; 31(2):139-52. PubMed ID: 19177031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study.
    Musuamba FT; Mourad M; Haufroid V; Delattre IK; Verbeeck RK; Wallemacq P
    Ther Drug Monit; 2009 Dec; 31(6):734-42. PubMed ID: 19855314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters.
    Takeuchi H; Okuyama K; Konno O; Jojima Y; Akashi I; Nakamura Y; Iwamoto H; Hama K; Iwahori T; Uchiyama M; Ashizawa T; Matsuno N; Nagao T; Hirano T; Oka K
    Transplant Proc; 2005 May; 37(4):1745-7. PubMed ID: 15919452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in liver biopsies after hepatic transplantation: correlation with histopathologic staging of rejection.
    Capron A; Lerut J; Verbaandert C; Mathys J; Ciccarelli O; Vanbinst R; Roggen F; De Reyck C; Lemaire J; Wallemacq PE
    Ther Drug Monit; 2007 Jun; 29(3):340-8. PubMed ID: 17529892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circadian and time-dependent variability in tacrolimus pharmacokinetics.
    Park SI; Felipe CR; Pinheiro-Machado PG; Garcia R; Tedesco-Silva H; Medina-Pestana JO
    Fundam Clin Pharmacol; 2007 Apr; 21(2):191-7. PubMed ID: 17391292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in peripheral blood mononuclear cells.
    Capron A; Musuamba F; Latinne D; Mourad M; Lerut J; Haufroid V; Wallemacq PE
    Ther Drug Monit; 2009 Apr; 31(2):178-86. PubMed ID: 19057467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus pharmacokinetics in lung transplantation: new strategies for monitoring.
    Ragette R; Kamler M; Weinreich G; Teschler H; Jakob H
    J Heart Lung Transplant; 2005 Sep; 24(9):1315-9. PubMed ID: 16143250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and evaluation of a simulation procedure to take into account various assays for the Bayesian dose adjustment of tacrolimus.
    Saint-Marcoux F; Debord J; Parant F; Labalette M; Kamar N; Rostaing L; Rousseau A; Marquet P
    Ther Drug Monit; 2011 Apr; 33(2):171-7. PubMed ID: 21383655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flexible limited sampling model for monitoring tacrolimus in stable patients having undergone liver transplantation with samples 4 to 6 hours after dosing is superior to trough concentration.
    Langers P; Press RR; den Hartigh J; Cremers SC; Baranski AG; Lamers CB; Hommes DW; van Hoek B
    Ther Drug Monit; 2008 Aug; 30(4):456-61. PubMed ID: 18641539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drug monitoring of tacrolimus in early stage after heart transplantation.
    Aidong W; Zhenjie C; Tong L; Lei Z; Yin W; Shanqi Z; Liping T
    Transplant Proc; 2004 Oct; 36(8):2388-9. PubMed ID: 15561258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral.
    Wang CH; Ko WJ; Chou NK; Wang SS
    Transplant Proc; 2004 Oct; 36(8):2386-7. PubMed ID: 15561257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report.
    Brunet M; van Gelder T; Åsberg A; Haufroid V; Hesselink DA; Langman L; Lemaitre F; Marquet P; Seger C; Shipkova M; Vinks A; Wallemacq P; Wieland E; Woillard JB; Barten MJ; Budde K; Colom H; Dieterlen MT; Elens L; Johnson-Davis KL; Kunicki PK; MacPhee I; Masuda S; Mathew BS; Millán O; Mizuno T; Moes DAR; Monchaud C; Noceti O; Pawinski T; Picard N; van Schaik R; Sommerer C; Vethe NT; de Winter B; Christians U; Bergan S
    Ther Drug Monit; 2019 Jun; 41(3):261-307. PubMed ID: 31045868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of different pharmacokinetics between cyclosporine and tacrolimus in renal transplant recipients: why cyclosporine is monitored by C2 level and tacrolimus by trough level.
    Takeuchi H; Matsuno N; Hirano T; Toraishi T; Konno O; Nakamura Y; Iwamoto H; Hama K; Unezaki S; Nagao T
    Transplant Proc; 2008 Sep; 40(7):2240-2. PubMed ID: 18790203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure.
    Saint-Marcoux F; Woillard JB; Jurado C; Marquet P
    Ther Drug Monit; 2013 Jun; 35(3):322-7. PubMed ID: 23666572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2004; 43(10):623-53. PubMed ID: 15244495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacodynamic investigation of tacrolimus in pediatric liver transplantation.
    Staatz CE; Taylor PJ; Lynch SV; Tett SE
    Liver Transpl; 2004 Apr; 10(4):506-12. PubMed ID: 15048793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of tacrolimus concentrations in peripheral blood mononuclear cells: application to cardiac transplant recipients.
    Lemaitre F; Antignac M; Fernandez C
    Clin Biochem; 2013 Oct; 46(15):1538-41. PubMed ID: 23454394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships of tacrolimus pharmacokinetic measures and adverse outcomes in stable adult liver transplant recipients.
    Dansirikul C; Staatz CE; Duffull SB; Taylor PJ; Lynch SV; Tett SE
    J Clin Pharm Ther; 2006 Feb; 31(1):17-25. PubMed ID: 16476116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of limited sampling strategies for tacrolimus.
    Op den Buijsch RA; van de Plas A; Stolk LM; Christiaans MH; van Hooff JP; Undre NA; van Dieijen-Visser MP; Bekers O
    Eur J Clin Pharmacol; 2007 Nov; 63(11):1039-44. PubMed ID: 17712551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients.
    Andrews LM; Li Y; De Winter BCM; Shi YY; Baan CC; Van Gelder T; Hesselink DA
    Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1225-1236. PubMed ID: 29084469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.